Question for written answer E-002555/2023
to the Commission
Rule 138
Harald Vilimsky (ID), **Georg Mayer** (ID)

Subject: Authorisation of a new vaccine against COVID-19

The European Medicines Agency has recommended authorising a new adapted COVID-19 vaccine developed by Biontech/Pfizer.

1. Does the Commission plan to purchase the new adapted vaccine and, if so, how many doses and at what price?

2. What lines of communication are there at present between the Commission and the Biontech/Pfizer group, and who is involved in the discussions?

3. Does the Commission share the view of the Standing Committee on Vaccination in Germany, which recommends a booster vaccination against COVID-19 only for certain groups of people, or does it support the idea that everyone should receive a booster vaccination?

Submitted: 6.9.2023